Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Marc Le Bozec, Charles Lee, Ruby Gadelrab

Premium

French cell chip maker Cytoo has named Marc Le Bozec as its new CEO.

Before joining Cytoo, Le Bozec was CEO and CFO of Cellectis' bioresearch subsidiary. He also served as chief operating officer at Alfact Innovation, and founded and led BioProtein Technologies.

Le Bozec sits on the scientific advisory board of INSERM, the French National Institute of Health and Medical Research. He graduated from the HEC School of Management in Paris.


Charles Lee has been appointed scientific director of the Jackson Laboratory for Genomic Medicine. Lee is the director of the Molecular Genetics Research Unit at Brigham and Women's Hospital and also directs the Cytogenetic Research Laboratory at Harvard Medical School. He holds a PhD from the University of Alberta in Canada.


Ruby Gadelrab has taken on a senior role in marketing and development at Invitae. She recently served as senior director of marketing for international markets at Affymetrix. She also has held positions at Dharmacon, Serologicals, Life Technologies, and Invitrogen.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.